VAXFORM, LLC

Biotech · Private

Orally administered recombinant subunit vaccine for COVID-19 using novel microencapsulation and spray-drying delivery platform

Grants
$481K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphteria-Tetanus-Pertussis vaccine$225,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Development of an oral recombinant subunit vaccine to protect against COVID-19$256,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2754Curevo Vaccine——
2755SERODOPA THERAPEUTICS INC——
2756CASTAG BIOSCIENCES, INC.——
2757VAXFORM, LLC——
2758LINNAEUS BIOSCIENCE, INC.——
2759Lassen Therapeutics——
2760ORGANIX, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 7
  • Adjuvant System For Oral Vaccine Administrationapplication
  • Vaccine System For Vaccine Adjuvantapplication
  • Adjuvant System for Vaccine Administrationapplication
  • Adjuvant System For Oral Vaccine Administrationapplication
  • Adjuvant System For Oral Vaccine Administrationapplication
  • Improved Adjuvant System For Oral Vaccine Adminstrationapplication
  • Improved Adjuvant System For Vaccine Administrationapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.